Suzhou Labyrinth Biotech Co., Ltd. is pleased to announce its participation in the World Conference on Lung Cancer (WCLC) 2025, held in Barcelona, Spain from September 6 to 9, where it will present its latest research findings in the form of an E-Poster.
Learn More >-网站_i0uyk9j7.jpg)
In August 2025, a team from Mass General Brigham (MGB) and Harvard Medical School published a comprehensive review titled “Circulating Tumor Cells: Blood-Based Detection, Molecular Biology, and Clinical Applications” in Cancer Cell, systematically summarizing the groundbreaking progress in the CTC field over the past decade. The review not only outlines the evolution of CTC detection technologies but also delves into the molecular biological characteristics of CTCs and their central role in dynamic tumor monitoring, treatment efficacy evaluation, and personalized therapy.
Learn More >
On August 12, 2023, the International Exchange and Cooperation Center of the National Health Commission, in collaboration with VB100, hosted the "2023 Medical Device Innovation and International Cooperation Summit." At the summit, Suzhou Labyrinth Biotech was awarded the "VB-Find Award: 2023 Most Innovative Medical Device Product (Solution)" for its original rare cell sorting and enrichment technology.
Learn More >_GuweMAnr.jpg)
This symposium features Prof. Majid E. Warkiani, a globally renowned microfluidics expert and Chief Technology Officer of Labyrinth, as the keynote speaker. He will highlight the revolutionary applications of "Label-Free Viable Rare Tumor Cell Microfluidic Technology" in rare cell isolation, precision oncology, stem cell therapy, and in vitro fertilization.
Learn More >
Recently, Professor Yu Hanry, a distinguished tenured professor at the National University of Singapore (NUS) and an internationally acclaimed expert in biomedical imaging and precision medicine, visited Suzhou Labyrinth Biotech Co.,Ltd.
Learn More >
July 18, 2025 – Labyrinth, in collaboration with Peking Union Medical College Hospital, has been granted a Chinese invention patent (No. ZL2025 1 0480497.X) for its "Human PDAC Ascites-Derived Tumor Cell Line and Applications".
Learn More >![[Invitation] International Microfluidics Symposium | Labyrinth & NUS Jointly Explore a New Era in Label-Free Rare Tumor Cell Capture](/UserFiles/Article/News/Seminar NUS-Labyrinth new3(2)(1)_INZSl2eH.jpg)
Microfluidics technology, serving as a critical bridge between conventional laboratory techniques and cutting-edge biological research, is increasingly demonstrating its immense potential in precision medicine applications. To foster academic exchange and technological advancement in this field, Suzhou Labyrinth Biotech Co., Ltd. and the National University of Singapore (NUS) Yong Loo Lin School of Medicine jointly organized the international symposium on 'Label-Free Microfluidic System for Rare Circulating Tumor Cell Capture' on August 5, 2025.
Learn More >
From Stanford Professor to Terminal Patient: A Doctor's Dual Journey Exposes Lung Cancer's Racial Disparities
Learn More >
Cancer treatment has long been one of the greatest challenges in medical science, with identifying the most effective anti-cancer drugs for individual patients being particularly crucial. Today, we're proud to introduce a groundbreaking technology that could revolutionize cancer therapy - the CTC Drug Sensitivity Test.
Learn More >
